Browsing by Author HO HAN KIAT

Select a letter below to browse by last name or type
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Showing results 5 to 24 of 32 < previous   next >
Issue DateTitleAuthor(s)
Dec-2013Carbon nanotubes for delivery of small molecule drugsWong, B.S.; Yoong, S.L.; Jagusiak, A.; Panczyk, T.; Ho, H.K. ; Ang, W.H. ; Pastorin, G. 
2015Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injuryTan, Cheauyih; Saw, Tzuenyih; Fong, Cheewai; Ho, Han Kiat 
Jan-2014Current strategies for inhibiting FGFR activities in clinical applications: Opportunities, challenges and toxicological considerationsHo, H.K. ; Yeo, A.H.L.; Kang, T.S. ; Chua, B.T.
5-Dec-2013Cytokines as mediators of chemotherapy-associated cognitive changes: Current evidence, limitations and directions for future researchCheung, Y.T.; Lim, S.R.; Ho, H.K. ; Chan, A. 
Apr-2013Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testingHo, H.K. ; Németh, G.; Ng, Y.R.; Pang, E.; Szántai-Kis, C.; Zsákai, L.; Breza, N.; Greff, Z.; Horváth, Z.; Pató, J.; Szabadkai, I.; Szokol, B.; Baska, F.; Orfi, L.; Ullrich, A.; Kéri, G.; Chua, B.T.
Jun-2010Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytesSaha, S.; New, L.S. ; Ho, H.K. ; Chui, W.K. ; Chan, E.C.Y. 
Jun-2012Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidenceTeo, Y.L.; Saetaew, M.; Chanthawong, S.; Yap, Y.S.; Yong Chan, E.C. ; Ho, H.K. ; Chan, A. 
Jan-2014Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatinYoong, S.L.; Wong, B.S.; Zhou, Q.L.; Chin, C.F.; Li, J. ; Venkatesan, T. ; Ho, H.K. ; Yu, V.; Ang, W.H. ; Pastorin, G. 
15-Oct-2013Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human fecesPhua, L.C.; Koh, P.K.; Cheah, P.Y.; Ho, H.K. ; Chan, E.C.Y. 
4-Jun-2012Immobilisation of quantum dots by bio-orthogonal PCR amplification and labelling for direct gene detection and quantitationTian, Q. ; Wong, W.; Xu, Y.; Chan, Y. ; Ho, H.K. ; Pastorin, G. ; Ang, W.H. 
2016Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer PatientsChae J.-W.; Ng T.; Yeo H.L.; Shwe M.; Gan Y.X.; HO HAN KIAT ; Chan A. 
2018Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson�s DiseaseBaek J.-S.; Tee J.K. ; Pang Y.Y. ; Tan E.Y.; Lim K.L. ; Ho H.K. ; Loo S.C.J.
Jul-2012Interaction of lapatinib with cytochrome P450 3A5Chan, E.C.Y. ; New, L.S. ; Chua, T.B.; Yap, C.W. ; Ho, H.K. ; Nelson, S.D.
Mar-2013Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapyPhua, L.C.; Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C.Y. ; Ho, H.K. 
1-Feb-2010Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicitySaha, S.; New, L.S. ; Ho, H.K. ; Chui, W.K. ; Chan, E.C.Y. 
23-Mar-2012Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinomaPoh, W.; Wong, W.; Ong, H.; Aung, M.O.; Lim, S.G.; Chua, B.T.; Ho, H.K. 
2015Mechanism-based inactivation of CYP450 enzymes: A case study of lapatinibHo H.K ; Chan J.C.Y; Hardy K.D., Chan E.C.Y.
1-Feb-2015Mechanism-based inactivation of CYP450 enzymes: A case study of lapatinibHo, Han Kiat ; Chan, James Chun Yip; Hardy, Klarissa D.; Chan, Eric Chun Yong 
Oct-2010Mechanism-based inactivation of cytochrome P450 3A4 by lapatinibTeng, W.C.; Oh, J.W.; New, L.S. ; Wahlin, M.D.; Nelson, S.D.; Ho, H.K. ; Chan, E.C.Y. 
2015Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendationsTeo Y.L ; Ho H.K ; Chan A